LMNL - Liminal BioSciences discontinues fezagepras development

• Liminal BioSciences ( NASDAQ: LMNL ) said Thursday it discontinued development of fezagepras .
• The decision is based on results from the phase 1a single ascending dose clinical trial, which showed that fezagepras was significantly inferior to sodium phenylbutyrate as a nitrogen scavenger.
• The clinical trial, which began in May, was designed as a head-to-head comparison with sodium phenylbutyrate to evaluate whether fezagepras was worth developing.
• The decision to stop fezagepras' development was not based on safety concerns.

For further details see: